Trinity Biotech (TRIB) Competitors

Trinity Biotech (NASDAQ:TRIB) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, community ranking, media sentiment, analyst recommendations and dividends.

Which has more risk and volatility, TRIB or KPTI?

Trinity Biotech has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500.

Is TRIB or KPTI more profitable?

Trinity Biotech has a net margin of -34.39% compared to Karyopharm Therapeutics' net margin of -52.62%.

Company	Net Margins	Return on Equity	Return on Assets
Trinity Biotech	-34.39%	N/A	-21.37%
Karyopharm Therapeutics	-52.62%	N/A	-39.58%

Do analysts prefer TRIB or KPTI?

Karyopharm Therapeutics has a consensus target price of $43.20, suggesting a potential upside of 777.51%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Trinity Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinity Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Karyopharm Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has preferable earnings and valuation, TRIB or KPTI?

Trinity Biotech has higher earnings, but lower revenue than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinity Biotech	$61.56M	0.24	-$24.02M	-$2.82	-0.29
Karyopharm Therapeutics	$142.13M	0.30	-$143.10M	-$13.26	-0.37

Does the MarketBeat Community favor TRIB or KPTI?

Karyopharm Therapeutics received 209 more outperform votes than Trinity Biotech when rated by MarketBeat users. Likewise, 72.44% of users gave Karyopharm Therapeutics an outperform vote while only 69.79% of users gave Trinity Biotech an outperform vote.

Company	Underperform	Outperform
Trinity Biotech	Outperform Votes 335 69.79%	Underperform Votes 145 30.21%
Karyopharm Therapeutics	Outperform Votes 544 72.44%	Underperform Votes 207 27.56%

Do insiders and institutionals hold more shares of TRIB or KPTI?

79.0% of Trinity Biotech shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 8.2% of Trinity Biotech shares are held by company insiders. Comparatively, 3.0% of Karyopharm Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Does the media prefer TRIB or KPTI?

In the previous week, Karyopharm Therapeutics had 4 more articles in the media than Trinity Biotech. MarketBeat recorded 10 mentions for Karyopharm Therapeutics and 6 mentions for Trinity Biotech. Karyopharm Therapeutics' average media sentiment score of 0.23 beat Trinity Biotech's score of -0.12 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trinity Biotech	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Karyopharm Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Karyopharm Therapeutics beats Trinity Biotech on 9 of the 17 factors compared between the two stocks.